• 1
    Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:73946.
  • 2
    Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94:108337.
  • 3
    Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004; 172:58619.
  • 4
    Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:616976.
  • 5
    Seliger B, Ritz U, Abele R et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61:864750.
  • 6
    Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188:921.
  • 7
    Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:54955.
  • 8
    Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40:16607.
  • 9
    Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62:506975.
  • 10
    Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994; 54:24627.
  • 11
    Buhtoiarov IN, Lum HE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005; 174:601322.
  • 12
    Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006; 79:118192.
  • 13
    Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 2006; 176:30918.
  • 14
    Heckelsmiller K, Rall K, Beck S et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:38929.
  • 15
    Van Ojik HH, Bevaart L, Dahle CE et al. CpG-A and -B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003; 63:5595600.
  • 16
    Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 15:18405.
  • 17
    Yron I, Erlich R, Efrati M, Shohat L, Witz IP, Sahar E. Comparison of NK activity in mouse spleen and peripheral blood lymphocytes. Immunobiology 1988; 177:44959.
  • 18
    Neal ZC, Yang JC, Rakhmilevich AL et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 2004; 10:483947.
  • 19
    Tafani M, Minchenko DA, Serroni A, Farber JL. Induction of the mitochondrial permeability transition mediates the killing of HeLa cells by staurosporine. Cancer Res 2001; 61:245966.
  • 20
    Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32:195868.
  • 21
    Belardelli F, Gresser I, Maury C, Maunoury MT. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int J Cancer 1982; 30:8215.
  • 22
    Qiao B, Li B, Yang X et al. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation. Cell Mol Immunol 2005; 2:1305.
  • 23
    Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34:25162.
  • 24
    Lenert P, Goeken AJ, Ashman RF. Extended sequence preferences for oligodeoxyribonucleotide activity. Immunology 2006; 117:47481.
  • 25
    Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S. Defect of toll-like receptor 9-mediated activation in NC/Nga mouse macrophages. Immunol Lett 2006; 106:915.
  • 26
    Nardini E, Morelli D, Aiello P et al. CpG-oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. J Cell Physiol 2005; 204:88995.
  • 27
    Adachi Y, Kindzelskii AL, Petty AR et al. IFN-gamma primes RAW264 macrophages and human monocytes for enhanced oxidant production in response to CpG DNA via metabolic signaling: roles of TLR9 and myeloperoxidase trafficking. J Immunol 2006; 176:503340.
  • 28
    Beloeil L, Tomkowiak M, Angelov G, Walzer T, Dubois P, Marvel J. In vivo impact of CpG oligodeoxynucleotide on CD8 T cell primary responses and survival. J Immunol 2003; 171:29953002.
  • 29
    Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004; 172:606573.
  • 30
    Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 2005; 175:161927.
  • 31
    Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005; 65:700712.
  • 32
    Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003; 9:2693700.
  • 33
    Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9:310514.
  • 34
    Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003; 171:39416.
  • 35
    Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK(–) and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167:524753.
  • 36
    Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59:542932.
  • 37
    Koo GC, Peppard JR. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 1984; 3:3013.
  • 38
    Auf G, Carpentier AF, Chen L, Clanche CL, Delattre GY. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7:35403.
  • 39
    Krepler C, Wacheck V, Strommer S et al. CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model. J Invest Dermatol 2004; 122:38791.
  • 40
    Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65:343746.
  • 41
    Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DC. Cutting edge. Bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 1999; 163:40959.
  • 42
    Heinzel FP, Rerko RM, Ahmed F, Hujer AM. IFN-gamma-independent production of IL-12 during murine endotoxemia. J Immunol 1996; 157:45218.
  • 43
    Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 1997; 84:18593.
  • 44
    Turner JG, Rakhmilevich AL, Burdelya L et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 2001; 166:8994.
  • 45
    Shah JA, Darrah PA, Ambrozak DR et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 2003; 198:28191.
  • 46
    Hirt UA, Leist M. Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differ 2003; 10:115664.
  • 47
    Hortelano S, Dallaporta B, Zamzami N et al. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett 1997; 410:3737.
  • 48
    Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun 2001; 2:34955.
  • 49
    Ashkar AA, Rosenthal KL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002; 2:54556.
  • 50
    Auricchio G, Garg SK, Martino A et al. Role of macrophage phospholipase D in natural and CpG-induced antimycobacterial activity. Cell Microbiol 2003; 5:91320.